CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 23, 2017--
Pharmaceuticals, Inc. (NASDAQ: IRWD) will host a live webcast of its
R&D Day on Thursday, March 9, 2017 beginning at 9:00 a.m. Eastern Time.
Members of the Ironwood leadership team and external opinion leaders
will provide R&D and commercial insights into key Ironwood product
opportunities. The event is being held at Ironwood’s offices in
The event will be accessible through the Investors section of the
company’s website at www.ironwoodpharma.com.
To access the webcast, please log on to the Ironwood website at least 15
minutes prior to the start of the call to ensure adequate time for any
software downloads that may be required. Individuals interested in
participating in the call should dial (877) 643-7155 (U.S. and
Canada) or (914) 495-8552 (international) using conference ID number
The webcast will be available for replay via telephone starting March 9,
2017 at approximately 2:00 p.m. Eastern Time, running through 3:00 p.m.
Eastern Time on March 16, 2016. To listen to the replay, dial (855)
859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 75432701. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the webcast has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS-C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of
hyperuricemia associated with uncontrolled gout. We are also advancing a
pipeline of internally and externally generated innovative product
candidates in areas of significant unmet need, including uncontrolled
gastroesophageal reflux disease and vascular and fibrotic diseases.
Ironwood was founded in 1998 and is headquartered in Cambridge, Mass.
For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170223006598/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Director, Corporate Communications
Meredith Kaya, 617-374-5082